MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
This early-stage clinical trial is testing a special engineered virus designed to target and destroy cancer cells while protecting healthy tissue. Researchers want to find the safest and most effective dose of this viral therapy, both on its own and when combined with standard chemotherapy and immunotherapy medications.
Adults aged 18 and older with specific types of blood cancers, such as multiple myeloma, leukemia, or lymphoma, whose cancer has either returned or stopped responding to standard treatments may be able to join. Participants also need to meet specific health and prior-treatment requirements set by the study team.
Participants will receive the engineered virus therapy, potentially along with chemotherapy and immune-boosting medications, while being closely monitored by doctors. The study involves regular check-ups, imaging scans, blood tests, and sometimes bone marrow samples to track how the treatment is working and watch for side effects.
This study is currently recruiting patients and takes place at medical centers in Scottsdale, Arizona, and Rochester, Minnesota.
- 1Tests an engineered virus therapy designed to hunt down and kill cancer cells.
- 2Combines the viral treatment with chemotherapy and immunotherapy options.
- 3Currently recruiting patients in Arizona and Minnesota who have hard-to-treat blood cancers.
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.